Kyphon Inc
http://www.kyphon.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Kyphon Inc
Novartis’ Gene Therapy Luxturna Gets Routine Funding In Scotland
Scotland’s health technology assessment body has granted routine reimbursement to Novartis’ vision loss drug Luxturna after an interim funding period via its ultra-orphan pathway, while Chiesi’s Filsuvez is set to begin its journey on the same pathway.
Keeping Track: Return & Renewal At US FDA
Takeda’s TAK-721 is back, ARS Pharma will be back soon to appeal neffy complete response letter, US FDA’s Project Renewal brings Temodar labeling in current day, and more highlights from the Pink Sheet’s US FDA Performance Tracker.
Crinetics’ Paltusotine Future Appears Bright With First Phase III Acromegaly Readout
The once-daily oral somatostatin receptor type 2 (SST2) agonist outshined placebo in patients switching from standard of care, offering an attractive alternative to once-monthly injectables.
Paradigm Plots Revival Of Butterfly Skin Drug After Amicus Deal
Chiesi-owned Amryt and Krystal Biotech have approved treatments for epidermolysis bullosa but Paradigm CEO Robert Ryan tells Scrip that SD-101, a topical cream he helped develop over 20 years ago, has the potential to be offer a far more extensive and efficacious solution for many more sufferers.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice